Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

No previous study has investigated whether glucarpidase improves important clinical outcomes in patients with methotrexate-associated acute kidney injury (AKI).

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

acute kidney injury, severe gastrointestinal reactions, hypersensitivity, acute gallbladder disease, and pulmonary aspiration during anesthesia.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Acute kidney injury (AKI) may progress to chronic kidney disease, and there is an urgent need for approaches that improve the limited regeneration of the renal tubules after AKI.

SeaStar Medical plans to conduct an interim analysis at the trial’s 90-day primary endpoint with the first 100 subjects. Given the current pace of enrollment, the company anticipates a Data Safety ...

Patients with lymphoma or leukemia with methotrexate-induced acute kidney injury experienced improved renal outcomes ...